Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig

被引:44
作者
Ekborn, A [1 ]
Lindberg, A
Laurell, G
Wallin, I
Eksborg, S
Ehrsson, H
机构
[1] Karolinska Hosp, Dept Otorhinolaryngol Head & Neck Surg, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp, Karolinska Pharm, SE-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Woman & Child Hlth, SE-17176 Stockholm, Sweden
[4] Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden
关键词
ototoxicity; nephrotoxicity; cisplatin; monohydrated complex of cisplatin pharmacokinetics;
D O I
10.1007/s00280-002-0540-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate and compare the ototoxicity and nephrotoxicity of cisplatin and cis-diammineaquachloroplatinum(II) ion (monohydrated complex of cisplatin, MHC, formed in vivo by hydrolysis of cisplatin) after their separate administration to guinea pigs. Methods: A dose of 4 mg/kg body weight of MHC was deemed suitable for the toxicity evaluation after dose titration. Electrophysiological hearing thresholds (auditory brainstem response, ABR), plasma creatinine and weight were measured in three groups of animals before and after receiving MHC 4 mg/kg (0.0141 mmol/kg), cisplatin 4.24 mg/kg (0.0141 mmol/kg, i.e. equimolar dose) or cisplatin 8 mg/kg (0.0267 mmol/kg) as an i.v. bolus injection. Cisplatin and MHC were analysed using liquid chromatography with post-column derivatization. Results: Administration of MHC 4 mg/kg caused a moderate ABR threshold shift, a significant increase in creatinine and a significant weight loss, changes similar to those seen after administration of cisplatin 8 mg/kg. Animals given cisplatin 4.24 mg/kg had a slight increase in creatinine, but had no ABR threshold shift and gained weight during the experiment. The pharmacokinetic parameters of cisplatin and MHC were estimated after administration of cisplatin 4.24 mg/kg and MHC 4 mg/kg. The area under the blood-ultrafiltrate concentration versus time curve (AUC) for cisplatin after administration of MHC 4 mg/kg was 23% (56 +/- 5.0 mug.min.ml(-1)) (means +/- SD) of that after administration of cisplatin 4.24 mg/kg (240 25 mug.min.ml(-1)). The AUC for MHC after administration of cisplatin 4.24 mg/kg was 20% (30 +/- 4.9 mug.min.ml(-1)) of that after administration of MHC 4 mg/kg (149 26 mug.min.ml(-1)). Conclusions: MHC 4 mg/kg causes ototoxicity, nephrotoxicity and weight loss when administered to guinea pigs. The toxic effects were similar to those seen after administration of cisplatin 8 mg/kg and higher than those seen after administration of cisplatin 4.24 mg/kg.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 38 条
[1]   Pharmacokinetics of cisplatin and its monohydrated complex in humans [J].
Andersson, A ;
Fagerberg, J ;
Lewensohn, R ;
Ehrsson, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (08) :824-827
[2]   DETERMINATION OF CISPLATIN AND CIS-DIAMINEAQUA-CHLOROPLATINUM(II) ION BY LIQUID-CHROMATOGRAPHY USING POSTCOLUMN DERIVATIZATION WITH DIETHYLDITHIOCARBAMATE [J].
ANDERSSON, A ;
EHRSSON, H .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 652 (02) :203-210
[3]   DETERMINATION OF THE ACID DISSOCIATION-CONSTANT FOR CIS-DIAMMINEAQUACHLOROPLATINUM(II) ION - A HYDROLYSIS PRODUCT OF CISPLATIN [J].
ANDERSSON, A ;
HEDENMALM, H ;
ELFSSON, B ;
EHRSSON, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (06) :859-862
[4]   DIMERIZATION PROCESSES OF CIS-[PT(NH3)2(H2O)2]2+ IN AQUEOUS-SOLUTION [J].
BIGNOZZI, CA ;
BARTOCCI, C ;
CHIORBOLI, C ;
CARASSITI, V .
INORGANICA CHIMICA ACTA-ARTICLES, 1983, 70 (01) :87-90
[5]   Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer [J].
Bokemeyer, C ;
Berger, CC ;
Hartmann, JT ;
Kollmannsberger, C ;
Schmoll, HJ ;
Kuczyk, MA ;
Kanz, L .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1355-1362
[6]   HEARING THRESHOLDS IN THE RABBIT - A BEHAVIORAL AND ELECTRO-PHYSIOLOGICAL STUDY [J].
BORG, E ;
ENGSTROM, B .
ACTA OTO-LARYNGOLOGICA, 1983, 95 (1-2) :19-26
[7]   STATISTICAL ESTIMATIONS IN PHARMACOKINETICS [J].
BOXENBAU.HG ;
RIEGELMA.S ;
ELASHOFF, RM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02) :123-148
[8]  
COMIS RL, 1994, SEMIN ONCOL, V21, P109
[9]   Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[10]   CISPLATIN METABOLITES IN PLASMA, A STUDY OF THEIR PHARMACOKINETICS AND IMPORTANCE IN THE NEPHROTOXIC AND ANTITUMOUR ACTIVITY OF CISPLATIN [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (19) :3063-3070